thalidomide and Anemia, Cooley's studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

Excerpt	Relevance	Reference
"To assess the efficacy and safety of thalidomide in children with transfusion-dependent thalassemia."	8.02	Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia. ( Chandra, J; Goel, M; Parakh, N; Pemde, H; Sharma, S; Singh, N, 2021)
"β-thalassemia major is a hereditary anemia resulting from defects in β-globin production."	5.46	Thalidomide-induced Stroke in a Child With Thalassemia Major. ( Gunaseelan, S; Prakash, A, 2017)
"To assess the efficacy and safety of thalidomide in children with transfusion-dependent thalassemia."	4.02	Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia. ( Chandra, J; Goel, M; Parakh, N; Pemde, H; Sharma, S; Singh, N, 2021)
" Mild adverse events were reported in 48 (9%) patients and serious adverse events, including cerebral vascular accident and portal vein thrombosis were reported in two patients each."	3.30	Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study. ( Ali, M; Ali, Z; Ismail, M; Khan, MTM; Rani, GF; Rehman, IU, 2023)
" The secondary endpoints included the red blood cell (RBC) units transfused and adverse effects."	3.01	Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial. ( Cai, N; Chen, JM; Chen, SJ; Chen, SY; Chen, XQ; He, S; Hu, ML; Huang, K; Huang, L; Huang, Y; Li, GH; Li, JM; Li, JY; Li, RL; Liu, J; Liu, SH; Lu, QY; Luo, TY; Qu, LW; Tan, Y; Wang, GZ; Wang, WD; Wei, JH; Wu, WQ; Xu, JQ; Xu, WW; Yang, HJ; Zhou, GB; Zhou, MG; Zhu, WJ, 2021)
"Thalidomide alone was also more effective in decreasing H3K27 methylation."	2.78	Evaluation of H3 histone methylation and colony formation in erythroid progenitors treated with thalidomide and sodium butyrate. ( Abroun, S; Ahmadvand, M; Chegeni, R; Fard, AD; Hajifathali, A; Kaviani, S; Mohammadi, MM; Noruzinia, M; Saki, N; Soleimani, M; Zonoubi, Z, 2013)
"Hydroxyurea (HU) has demonstrated promising outcomes; additionally, thalidomide has also shown improvement in hemoglobin (Hb) levels for patients with β-thalassemia in some studies."	1.72	Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia. ( Adil, SO; Ansari, AH; Ansari, I; Ansari, SH; Ansari, UH; Farooq, F; Hussain, Z; Khawaja, S; Masqati, NU; Sattar, A; Wasim, M; Zohaib, M, 2022)
" No severe adverse effects was reported by patients of any group."	1.62	Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India. ( Baul, SN; Chakrabarti, P; De, R; Dolai, TK; Ghosh, P; Jain, M; Mandal, PK, 2021)
"Thalidomide has been shown to reactivate fetal hemoglobin (HbF) production and reduce the need for blood transfusions in β-thalassemia patients."	1.56	The association of HBG2, BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese β-thalassemia patients. ( Ma, Y; Wu, Y; Xiao, J; Yang, K; Yin, X; Zhou, Y, 2020)
"β-thalassemia major is a hereditary anemia resulting from defects in β-globin production."	1.46	Thalidomide-induced Stroke in a Child With Thalassemia Major. ( Gunaseelan, S; Prakash, A, 2017)
"Sickle-cell disease (SCD) and beta thalassemia constitute worldwide public health problems."	1.35	Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. ( Brady, H; Chan, K; Corral, LG; Ferguson, GD; Glezer, E; Jensen-Pergakes, K; Morris, CL; Moutouh-de Parseval, LA; Muller, G; Verhelle, D, 2008)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (4.35)	29.6817
2010's	9 (39.13)	24.3611
2020's	13 (56.52)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia: a Quasi Randomized Control Trial in a Tertiary Care Hospital in Bangladesh[NCT06098014]	Phase 3	60 participants (Anticipated)	Interventional	2023-03-08	Recruiting
Efficacy and Safety of Combination of Hydroxyurea and Low-dose Thalidomide on Hemoglobin Synthesis in Thalassemia Patients[NCT05132270]	Phase 2/Phase 3	135 participants (Actual)	Interventional	2020-01-01	Completed
Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients: A Pharmacodynamics and Pharmacogenetics Analysis[NCT06146478]	Phase 3	200 participants (Actual)	Interventional	2022-01-25	Completed
Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia Patients of Pakistan[NCT03651102]	Phase 2/Phase 3	654 participants (Actual)	Interventional	2018-01-01	Completed
The Multi-center Clinical Trials of Thalidomide in TI[NCT03184844]	Phase 2	100 participants (Anticipated)	Interventional	2017-05-02	Recruiting
The Phase II Clinical Trials of Thalidomide in NTDT[NCT02995707]	Phase 2	30 participants (Anticipated)	Interventional	2016-09-30	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Drug safety in thalassemia: lessons from the present and directions for the future. Expert opinion on drug safety, 2021, Volume: 20, Issue:8 Topics: Activin Receptors, Type II; beta-Thalassemia; Hematinics; Humans; Hydroxyurea; Immunoglobulin Fc Fra	2021
Induction of fetal hemoglobin as a novel therapeutic strategy for β-hemoglobinopathy. Laboratory hematology : official publication of the International Society for Laboratory Hematology, 2014, Mar-01, Volume: 20, Issue:1 Topics: Anemia, Sickle Cell; Angiogenesis Inhibitors; Animals; beta-Thalassemia; Butyric Acid; Drug Synergis	2014
Foetal haemoglobin inducers and thalassaemia: novel achievements. Blood transfusion = Trasfusione del sangue, 2010, Volume: 8, Issue:1 Topics: Angiogenesis Inhibitors; beta-Thalassemia; Fetal Hemoglobin; Genotype; Humans; Thalidomide	2010

Article	Year
Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial. Signal transduction and targeted therapy, 2021, 11-18, Volume: 6, Issue:1 Topics: Adolescent; Adult; beta-Thalassemia; Child; Double-Blind Method; Erythrocyte Transfusion; Female; Hu	2021
Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study. Scientific reports, 2023, 08-21, Volume: 13, Issue:1 Topics: beta-Thalassemia; Ferritins; Humans; Hydroxyurea; Thalidomide; Treatment Outcome; Uric Acid	2023
Safety and effectiveness of thalidomide and hydroxyurea combination in β-thalassaemia intermedia and major: a retrospective pilot study. British journal of haematology, 2020, Volume: 188, Issue:3 Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Female; Humans; Hydroxyurea; Male; Ret	2020
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adolescent; Adult; beta-Thalassemia; Blood Cell Count; Female; Fetal Hemoglobin; Humans; Male; Retic	2018
Evaluation of H3 histone methylation and colony formation in erythroid progenitors treated with thalidomide and sodium butyrate. Laboratory hematology : official publication of the International Society for Laboratory Hematology, 2013, Volume: 19, Issue:1 Topics: AC133 Antigen; Anemia, Sickle Cell; Antigens, CD; beta-Thalassemia; Butyrates; Cells, Cultured; Eryt	2013

Article	Year
Safety: A Primary Concern in Thalidomide Use in Thalassemia: Reply. Indian pediatrics, 2021, 11-15, Volume: 58, Issue:11 Topics: beta-Thalassemia; Humans; Thalassemia; Thalidomide	2021
Safety: A Primary Concern in Thalidomide Use in Thalassemia. Indian pediatrics, 2021, 11-15, Volume: 58, Issue:11 Topics: beta-Thalassemia; Humans; Thalassemia; Thalidomide	2021
Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia. Blood advances, 2022, 12-27, Volume: 6, Issue:24 Topics: beta-Thalassemia; Blood Transfusion; Child; Combined Modality Therapy; Female; Humans; Hydroxyurea;	2022
[Predictors of Hematologic Responses in Patients with Non-Transfusion-Dependent β-Thalassemia Receiving Thalidomide Therapy]. Zhongguo shi yan xue ye xue za zhi, 2022, Volume: 30, Issue:5 Topics: beta-Thalassemia; Fetal Hemoglobin; Humans; MicroRNAs; Polymorphism, Single Nucleotide; Repressor Pr	2022
High-level induction of fetal haemoglobin by pomalidomide in β-thalassaemia/HbE erythroid progenitor cells. British journal of haematology, 2020, Volume: 189, Issue:6 Topics: beta-Thalassemia; Erythroid Precursor Cells; Fetal Hemoglobin; Gene Expression Regulation; Hemoglobi	2020
The association of HBG2, BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese β-thalassemia patients. Blood cells, molecules & diseases, 2020, Volume: 84 Topics: Adult; Asian People; beta-Thalassemia; Female; Fetal Hemoglobin; Humans; Immunosuppressive Agents; M	2020
Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India. Blood cells, molecules & diseases, 2021, Volume: 88 Topics: Adolescent; Adult; Antisickling Agents; beta-Thalassemia; Child; Female; Hemoglobin E; Hemoglobins;	2021
Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients. Annals of hematology, 2021, Volume: 100, Issue:6 Topics: Adolescent; Adult; Antisickling Agents; beta-Thalassemia; Blood Transfusion; Child; Drug Combination	2021
Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia. Indian pediatrics, 2021, Jul-15, Volume: 58, Issue:7 Topics: Adolescent; beta-Thalassemia; Child; Hemoglobins; Humans; Prospective Studies; Thalassemia; Thalidom	2021
Thalidomide-induced Stroke in a Child With Thalassemia Major. Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:8 Topics: beta-Thalassemia; Blood Coagulation Tests; Brain; Child; Combined Modality Therapy; Female; Humans;	2017
Thalidomide has a significant effect in patients with thalassemia intermedia. Hematology (Amsterdam, Netherlands), 2018, Volume: 23, Issue:1 Topics: Adult; beta-Thalassemia; Female; Humans; Immunosuppressive Agents; Male; Thalidomide	2018
Thalidomide induces haematologic responses in patients with β-thalassaemia. European journal of haematology, 2017, Volume: 99, Issue:5 Topics: Adolescent; Adult; Aged; beta-Thalassemia; Biomarkers; Blood Transfusion; Combined Modality Therapy;	2017
Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia. Expert review of hematology, 2013, Volume: 6, Issue:3 Topics: Antisickling Agents; Azacitidine; beta-Globins; beta-Thalassemia; Decitabine; Fetal Hemoglobin; Gene	2013
Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy. Blood transfusion = Trasfusione del sangue, 2010, Volume: 8, Issue:1 Topics: Adult; beta-Thalassemia; Female; Humans; Immunosuppressive Agents; Thalidomide	2010
Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy. Blood transfusion = Trasfusione del sangue, 2010, Volume: 8, Issue:1 Topics: Adult; beta-Thalassemia; Female; Humans; Immunosuppressive Agents; Thalidomide	2010
Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy. Blood transfusion = Trasfusione del sangue, 2010, Volume: 8, Issue:1 Topics: Adult; beta-Thalassemia; Female; Humans; Immunosuppressive Agents; Thalidomide	2010
Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy. Blood transfusion = Trasfusione del sangue, 2010, Volume: 8, Issue:1 Topics: Adult; beta-Thalassemia; Female; Humans; Immunosuppressive Agents; Thalidomide	2010
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. The Journal of clinical investigation, 2008, Volume: 118, Issue:1 Topics: Anemia, Sickle Cell; Antigens, CD34; Antineoplastic Agents; Antisickling Agents; beta-Thalassemia; B	2008

thalidomide and Anemia, Cooley's

Research Excerpts

Research

Studies (23)

Authors

Clinical Trials (6)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Chen, JM	1
Zhu, WJ	1
Liu, J	1
Wang, GZ	1
Chen, XQ	1
Tan, Y	1
Xu, WW	1
Qu, LW	1
Li, JY	1
Yang, HJ	1
Huang, L	2
Cai, N	2
Wang, WD	1
Huang, K	1
Xu, JQ	1
Li, GH	1
He, S	1
Luo, TY	1
Huang, Y	2
Liu, SH	1
Wu, WQ	1
Lu, QY	1
Zhou, MG	1
Chen, SY	1
Li, RL	1
Hu, ML	1
Wei, JH	1
Li, JM	1
Chen, SJ	1
Zhou, GB	1
Chandra, J	2
Khera, S	1
Ansari, SH	1
Ansari, I	1
Wasim, M	1
Sattar, A	1
Khawaja, S	1
Zohaib, M	1
Hussain, Z	1
Adil, SO	1
Ansari, AH	1
Ansari, UH	1
Farooq, F	1
Masqati, NU	1
Yang, K	2
Yin, XL	2
Liu, XD	1
Hua, F	1
Peng, W	1
Li, L	1
Chen, K	1
Zhang, J	1
Luo, S	1
Xiao, J	2
Ali, Z	1
Ismail, M	1
Rehman, IU	1
Rani, GF	1
Ali, M	1
Khan, MTM	1
Shah, S	1
Sheth, R	1
Shah, K	1
Patel, K	1
Khamphikham, P	1
Nualkaew, T	1
Pongpaksupasin, P	1
Kaewsakulthong, W	1
Songdej, D	1
Paiboonsukwong, K	1
Engel, JD	1
Hongeng, S	1
Fucharoen, S	1
Sripichai, O	1
Jearawiriyapaisarn, N	1
Wu, Y	1
Ma, Y	1
Zhou, Y	2
Yin, X	2
Jain, M	1
Chakrabarti, P	1
Dolai, TK	1
Ghosh, P	1
Mandal, PK	1
Baul, SN	1
De, R	1
Bhurani, D	1
Kapoor, J	1
Yadav, N	1
Khushoo, V	1
Agrawal, N	1
Ahmed, R	1
Arora, JS	1
Mehta, P	1
Grech, L	1
Sultana, J	1
Borg, K	1
Borg, J	1
Parakh, N	1
Singh, N	1
Sharma, S	1
Goel, M	1
Pemde, H	1
Gunaseelan, S	1
Prakash, A	1
Li, Y	1
Ren, Q	2
Li, P	1
Lin, W	1
Chen, J	1
Zhu, W	1
Bu, S	1
Li, J	1
Zhou, YL	1
Wang, L	1
Chen, YS	1
Ma, YN	1
Li, PP	1
Fard, AD	2
Kaviani, S	2
Noruzinia, M	2
Soleimani, M	1
Abroun, S	1
Chegeni, R	1
Hajifathali, A	1
Zonoubi, Z	1
Ahmadvand, M	1
Mohammadi, MM	1
Saki, N	2
Breda, L	1
Rivella, S	1
Zuccato, C	1
Gambari, R	2
Mortaz, E	1
Masera, N	1
Tavecchia, L	1
Capra, M	1
Cazzaniga, G	1
Vimercati, C	1
Pozzi, L	1
Biondi, A	1
Masera, G	1
Moutouh-de Parseval, LA	1
Verhelle, D	1
Glezer, E	1
Jensen-Pergakes, K	1
Ferguson, GD	1
Corral, LG	1
Morris, CL	1
Muller, G	1
Brady, H	1
Chan, K	1